Biotech · Private company
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Track this companyFree. Adds ImmunoVaccine Technologies, Inc. (IMV Inc.) to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- CPAPhase 2 · Relapsed Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Recurrent Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Cyclophosphamide 50mgPhase 2 · Platinum-resistant Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- DPX-SurvivacPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- DPX-SurvivacPhase 2 · Recurrent Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- DPX-SurvivacPhase 2 · Relapsed Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Epacadostat (INCB024360)Phase 2 · Recurrent Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Maveropepimut-SPhase 2 · Platinum-resistant Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Relapsed Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- DPX-SurvivacPhase 1 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- DPX-Survivac(Aqueous)Phase 1 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian CancerPHASE2 · TERMINATED · started Aug 5, 2022ClinicalTrials.gov NCT05243524 · fetched Nov 12, 2026
- DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell LymphomaPHASE2 · RECRUITING · started Jun 18, 2021ClinicalTrials.gov NCT04920617 · fetched Nov 12, 2026
- Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 21, 2018ClinicalTrials.gov NCT03836352 · fetched Nov 12, 2026
- Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian CancerPHASE1_PHASE2 · UNKNOWN · started Apr 1, 2016ClinicalTrials.gov NCT02785250 · fetched Nov 12, 2026
- Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal CancerPHASE1 · COMPLETED · started Aug 23, 2013ClinicalTrials.gov NCT03332576 · fetched Nov 12, 2026